Modulating carbohydrate–protein interactions through glycoengineering of monoclonal antibodies to impact cancer physiology

Austin W.T. Chiang, Shangzhong Li, Philipp N. Spahn, Anne Richelle, Chih-Chung Kuo, Mojtaba Samoudi, Nathan E. Lewis

Research output: Contribution to journalJournal articleResearchpeer-review

267 Downloads (Pure)

Abstract

Diverse glycans on proteins impact cell and organism physiology, along with drug activity. Since many protein-based biotherapeutics are glycosylated and these glycans have biological activity, there is a desire to engineer glycosylation for recombinant protein-based biotherapeutics. Engineered glycosylation can impact the recombinant protein efficacy and also influence many cell pathways by first changing glycan–protein interactions and consequently modulating disease physiologies. However, its complexity is enormous. Recent advances in glycoengineering now make it easier to modulate protein-glycan interactions. Here, we discuss how engineered glycans contribute to therapeutic monoclonal antibodies (mAbs) in the treatment of cancers, how these glycoengineered therapeutic mAbs affect the transformed phenotypes and downstream cell pathways. Furthermore, we suggest how systems biology can help in the next generation mAb glycoengineering process by aiding in data analysis and guiding engineering efforts to tailor mAb glycan and ultimately drug efficacy, safety and affordability.
Original languageEnglish
JournalCurrent Opinion in Structural Biology
Volume40
Pages (from-to)104-111
ISSN0959-440X
DOIs
Publication statusPublished - 2016

Fingerprint Dive into the research topics of 'Modulating carbohydrate–protein interactions through glycoengineering of monoclonal antibodies to impact cancer physiology'. Together they form a unique fingerprint.

Cite this